SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) exists to solve a specific problem: how do you gain broad exposure to pharmaceutical companies without the concentration risk of the largest healthcare names dominating your returns? XPH holds 57 positions with relatively even weighting-no single stock exceeds 2.12% of the portfolio. That structure delivers pure-play pharma exposure spanning large-cap stalwarts like Eli Lilly and Company () and Merck & Co. (), mid-cap specialty pharmaceutical companies, and smaller biotech names focused on niche therapeutics.
Brevan Howard, the long-running macro investment manager with $33 billion in assets, finished 2025 looking up at many of its macro peers and multistrategy rivals. The firm's two largest funds - Alpha Strategies and Master, each of which runs roughly $11 billion - finished 2025 with gains of 8% and 0.8%, respectively, a person close to the firm told Business Insider. The firm's smaller Emerging Markets strategy was a bright spot, returning more than 15% over the year, the person added.
Out of more than 18,400 money managers worldwide, just 12.9% are women, compared with 12.5% last year and 10.3% in 2016. The absolute value of assets managed by women has tripled over the past ten years to £4 trillion, but this growth reflects a rise in mixed-gender teams, which now manage almost 15% of funds, up from just 6.7% a decade ago.